CureTelligence
AI-based Pill Identification
Company Overview
Snapshot
Founded in September 2022 by Vadim Zelikman, CureTelligence operates with 1–10 employees and has raised $950,000 across one funding round. The company received a grant from the BIRD Foundation in July 2022.
Business overview
CureTelligence develops DoseBot, a robotic system designed to enhance medication safety by preventing errors in identification, dispensing, and administration. The platform integrates hardware and software with highly accurate multispectral tools and AI algorithms to identify pills and control dispensing processes. Serving the Health Tech & Life Sciences sector, CureTelligence focuses on digital healthcare and medical devices, utilizing deep learning, machine learning, and data analytics to address medication management challenges in markets including the United States, Israel, Europe, and Japan.
Log in to access full profile ›Company Intelligence Q&A
- What is CureTelligence's primary product?
- CureTelligence's primary product is DoseBot, a robotic system that uses AI and multispectral tools for safe and accurate medication identification, dispensing, and administration.
- When was CureTelligence founded and by whom?
- CureTelligence was founded in September 2022 by Vadim Zelikman, who serves as Co-founder & CEO.
- What is the status of CureTelligence?
- CureTelligence is currently non-active and ceased to operate in December 2024.
- What is the total capital raised by CureTelligence?
- CureTelligence has raised a total of $950,000 across one funding round.
- Which markets does CureTelligence target?
- CureTelligence targets geomarkets including the United States, Israel, Europe, and Japan for its medication safety solutions.